SS-31 (Elamipretide) · Research brief
Elamipretide SS-31 Binds Cardiolipin: A Mechanism Review
Short answer
An elamipretide SS-31 binds cardiolipin mechanism review arrives at a single central claim: the tetrapeptide does not appear to act through a classical cell-surface or intracellular receptor, and instead associates with cardiolipin, the signature anionic phospholipid of the inner mitochondrial membrane, where studies report that it changes the local electrostatic and structural environment of the proteins cardiolipin organizes.
An elamipretide SS-31 binds cardiolipin mechanism review arrives at a single central claim: the tetrapeptide does not appear to act through a classical cell-surface or intracellular receptor, and instead associates with cardiolipin, the signature anionic phospholipid of the inner mitochondrial membrane, where studies report that it changes the local electrostatic and structural environment of the proteins cardiolipin organizes. That reframing, from an early description as a mitochondria-targeted antioxidant to a description as a cardiolipin-interacting peptide, is the most important development in the SS-31 elamipretide mechanism of action literature, and it is the reason searches for SS-31 elamipretide receptor binding return lipid chemistry rather than pharmacology of a defined binding pocket. What follows summarizes what the published work reports, in which models, and where the evidence stops.
What does the mechanism literature say SS-31 (elamipretide) actually does?
The literature describes SS-31 as a small, cell-permeable, positively charged tetrapeptide that accumulates in mitochondria and selectively associates with cardiolipin-containing membranes, with downstream effects on cytochrome c chemistry, cristae organization and electron transport efficiency.
SS-31 is the research designation for the peptide also known as elamipretide, with the sequence D-Arg-Dmt-Lys-Phe-NH2, where Dmt is 2',6'-dimethyltyrosine. The alternating arrangement of aromatic and basic residues gives the molecule a net positive charge at physiological pH along with two aromatic faces, and reviews of the compound class describe this aromatic-cationic motif as the structural basis for both cell permeability and membrane association.
The earliest published framing, in work such as the 2004 Journal of Biological Chemistry paper Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury, treated the peptide family as mitochondria-targeted radical scavengers whose activity derived from the phenolic Dmt residue. That interpretation dominated the first decade of work and is still repeated in secondary sources.
The later framing, developed in the 2013 Journal of the American Society of Nephrology study The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin and in the companion review First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics, treats cardiolipin association as the primary event and antioxidant chemistry as, at most, secondary. Research suggests the scavenging model could not account for activity at the low concentrations reported in isolated mitochondria, nor for the observation that structurally related peptides lacking the Dmt phenol retain protective activity in the same models.
So the short answer a mechanism review can defend is this: the peptide behaves as a lipid-interacting agent at the inner membrane interface, and the functional readouts, including oxygen consumption, ATP synthesis and membrane architecture, follow from that interaction rather than from stoichiometric radical quenching.
What is cardiolipin, and why is it the proposed target?
Cardiolipin is a dimeric phospholipid found almost exclusively in the inner mitochondrial membrane, and it is the proposed target because it is both the organizing lipid of the electron transport chain and the lipid whose oxidation marks mitochondrial failure.
Structurally, cardiolipin carries four acyl chains attached to two phosphatidyl moieties joined by a glycerol bridge, giving it a small head group relative to a bulky hydrophobic body. The literature on mitochondrial membrane biology describes this cone-like geometry as a driver of negative membrane curvature, which is why cardiolipin is enriched at the tightly folded cristae where oxidative phosphorylation takes place. Its phosphate groups make it anionic, so the cristae surface carries a distinctive negative surface charge that is unusual among cellular membranes.
Functionally, cardiolipin is described as a structural cofactor rather than a passive bilayer component. Reviews of mitochondrial bioenergetics report that cardiolipin molecules occupy defined positions on respiratory complexes, stabilize supercomplex assemblies, support the adenine nucleotide translocase and anchor cytochrome c to the membrane surface so that electron transfer between Complex III and Complex IV can proceed efficiently.
That same chemistry makes cardiolipin vulnerable. Its polyunsaturated acyl chains are oxidation-sensitive, and oxidized or hydrolyzed cardiolipin is reported to lose its capacity to hold respiratory complexes in productive arrangements. The 2014 British Journal of Pharmacology review First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics frames cardiolipin peroxidation as an early and self-amplifying step in ischemic and age-associated mitochondrial dysfunction, preceding permeability transition and cytochrome c release.
A compound that binds this lipid therefore has leverage over many processes at once without needing a protein receptor. The mechanism argument in the SS-31 literature is precisely this: by occupying the cardiolipin-rich interface, the peptide is reported to influence an entire membrane microenvironment rather than a single enzyme.
Does SS-31 have a receptor, or is the target a lipid?
No classical receptor has been identified for SS-31, and the published mechanism work treats cardiolipin, and anionic membrane surfaces more generally, as the binding partner rather than a protein with a defined ligand pocket.
This question recurs because of the compound's chemical lineage. The SS peptide series grew out of medicinal chemistry on Dmt-containing opioid analogs, and reviews of the series note that sequence order determines opioid activity: analogs with the aromatic Dmt residue at position one display opioid receptor agonism, whereas the SS-31 arrangement, with D-arginine first, is reported to lack that activity. The discovery narrative is laid out in the 2014 Clinical Pharmacology and Therapeutics review Serendipity and the discovery of novel compounds that restore mitochondrial plasticity, which describes mitochondrial uptake and protection as properties that emerged independently of receptor pharmacology.
So the honest answer to a question about SS-31 elamipretide receptor binding is that the term does not apply in its usual sense. There is no reported dissociation constant for a G protein-coupled receptor, no agonist-antagonist series and no knockout model that abolishes the effect by removing a receptor gene. What the literature reports instead are lipid-binding measurements in model membranes and liposomes, and protein proximity data obtained by chemical cross-linking.
The 2020 Journal of Biological Chemistry study The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action sharpened this point. It reports that the peptide partitions into bilayers containing anionic lipids and alters membrane surface charge, and it raises the possibility that cardiolipin is not strictly required for binding, since other anionic phospholipids support association as well. Under that model, cardiolipin matters because of where it is concentrated, not because it offers a unique recognition site.
For researchers, the practical consequence is methodological. Mechanistic experiments are designed around membrane composition, surface potential and protein-lipid contacts, not around receptor occupancy assays.
How does an SS-31 molecule reach the inner mitochondrial membrane?
Studies report that the peptide crosses plasma and mitochondrial membranes and concentrates in the inner membrane region in a manner described as not requiring a large membrane potential, which distinguishes it from lipophilic cation carriers.
Many mitochondria-targeted agents are delivered by conjugation to triphenylphosphonium or similar delocalized cations, which accumulate in proportion to the electrical gradient across the inner membrane. That strategy has a built-in limitation: in depolarized or injured mitochondria, the very condition such agents are meant to address, accumulation falls. Reviews of the SS peptide class, including the 2006 AAPS Journal review Cell-permeable, mitochondrial-targeted, peptide antioxidants, describe uptake of these peptides as concentration-driven and largely independent of potential, which the authors of that literature present as an advantage for ischemic models.
The proposed physical basis is electrostatic attraction to the anionic cristae surface combined with partial insertion of the aromatic residues into the hydrophobic interface. The 2014 British Journal of Pharmacology paper Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis describes the peptide as residing near the head group region rather than penetrating deeply into the acyl chain core, which is consistent with reports that it does not act as a detergent and does not permeabilize membranes at the concentrations studied.
Selectivity, in this account, is a consequence of lipid distribution. Cardiolipin is largely confined to mitochondria in healthy cells, so a peptide drawn to cardiolipin-rich bilayers is drawn to mitochondria. The 2020 lipid bilayer study complicates this slightly by showing broader anionic lipid binding in model systems, and the field has not fully resolved how much of the in-cell selectivity comes from lipid composition versus from the geometry and surface potential of cristae membranes.
All of this is reported from isolated mitochondria, liposomes and cultured cells. Quantitative partitioning in intact tissue remains less well characterized in the public literature.
Which structural features of the peptide drive cardiolipin association?
The alternating aromatic-cationic architecture is the reported driver: basic residues supply electrostatic attraction to the anionic phosphate head groups, while the aromatic residues provide hydrophobic contacts at the membrane interface.
The sequence D-Arg-Dmt-Lys-Phe-NH2 places the guanidinium group of D-arginine and the epsilon-amino group of lysine in alternation with two aromatic side chains. Reviews of the series describe this as a deliberate design feature inherited from the parent peptides, and the D-amino acid content and C-terminal amidation are described as contributing to resistance against aminopeptidase degradation.
Structure-activity comparisons within the series are informative about which features matter for which effect. The literature reports that SS-20, which lacks the Dmt residue and therefore lacks phenolic radical-scavenging chemistry, retains protective activity in several mitochondrial models, while peptides built with the aromatic residue in the first position behave as opioid agonists. Taken together, these comparisons are used in the 2014 reviews to argue that membrane association, not antioxidant chemistry and not receptor binding, is the shared functional property of the protective members of the series.
Biophysical work supports an interfacial binding mode. The 2020 Journal of Biological Chemistry bilayer study reports changes in membrane surface electrostatics upon peptide addition and uses modeling and spectroscopy to place the peptide at the head group interface, where it can shield or redistribute negative surface charge. That electrostatic modulation is the proposed proximate cause of the downstream protein effects, because many inner membrane proteins depend on surface charge for correct docking and conformational behavior.
The limitation here is that model membranes are simplifications. Liposomes composed of a few defined lipids do not reproduce the protein crowding, curvature and asymmetry of a real crista, and the field has not published a high-resolution structure of the peptide bound to a native inner membrane. The binding mode is therefore best described as an inference supported by converging biophysical measurements rather than as a solved structure.
How does the cardiolipin interaction change cytochrome c behavior?
Studies report that the peptide preserves cytochrome c as an electron carrier by limiting the cardiolipin-induced conformational change that converts it into a peroxidase.
Cytochrome c normally shuttles electrons between Complex III and Complex IV while loosely bound to the outer leaflet of the inner membrane. Its heme iron is coordinated by a methionine residue, and that coordination keeps the protein in a tightly folded, low-peroxidase state. The mitochondrial biochemistry literature describes a second mode of cytochrome c binding to cardiolipin in which an acyl chain inserts into a hydrophobic channel on the protein, loosening the fold, displacing the methionine-iron bond and unmasking peroxidase activity.
That peroxidase form is destructive in two directions. It oxidizes the surrounding cardiolipin, degrading the very scaffold that holds the respiratory chain together, and it loses efficiency as an electron shuttle, so respiration falls while reactive oxygen species rise. The 2015 Biochimica et Biophysica Acta study Disruption of cytochrome c heme coordination is responsible for mitochondrial injury during ischemia reports this loss of heme coordination as an early event in ischemic mitochondria, upstream of permeability transition.
The 2014 British Journal of Pharmacology paper on the cytochrome c and cardiolipin complex reports that SS-31 interferes with the peroxidase-promoting interaction while leaving the electron transfer function intact, and it frames this selectivity as the key pharmacological claim: the peptide does not strip cytochrome c from the membrane, and it does not block respiration, but it is reported to prevent the conformational conversion that uncouples the two roles.
The proposed physical explanation returns to surface electrostatics. By occupying the interface and altering charge distribution around the cardiolipin head groups, the peptide is reported to disfavor the deep hydrophobic insertion mode while permitting the shallow electrostatic docking needed for electron transfer. This is a plausible and well-argued model, but it rests largely on spectroscopic and functional readouts in isolated systems rather than on direct structural visualization of a ternary peptide-lipid-protein complex.
What do studies report about cristae architecture and electron transport?
Studies in injured and aged mitochondria report preserved or restored cristae structure together with improved coupling of oxygen consumption to ATP synthesis.
Cristae morphology is the structural readout most often used in this literature. The 2013 Journal of the American Society of Nephrology ischemia study reports that mitochondria from ischemic tissue show swollen matrices and disordered cristae, and that peptide exposure is associated with retained cristae architecture in electron microscopy images. Because cardiolipin curvature and supercomplex assembly are interdependent, the mechanism argument is that stabilizing the lipid stabilizes the folds, and stabilizing the folds keeps respiratory complexes in productive proximity.
The bioenergetic readouts reported alongside the morphology include oxygen consumption rates, respiratory control ratios and ATP recovery after ischemia. The 2011 Journal of the American Society of Nephrology study Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury reports faster restoration of ATP and reduced structural injury in a kidney ischemia-reperfusion model, and the 2013 study ties comparable functional recovery to the cardiolipin interaction.
An important nuance is that the literature does not describe the peptide as a stimulant of respiration in healthy mitochondria. The reported pattern is restoration toward control values in compromised preparations rather than supraphysiological increases in well-coupled ones, which is consistent with a mechanism that repairs an interface rather than one that drives an enzyme.
Limits are worth stating plainly. Cristae morphology scoring from electron microscopy is semi-quantitative and subject to preparation artifacts; respiratory measurements in isolated organelles remove the cellular context that governs substrate supply and calcium handling; and supercomplex assembly has been inferred more often than directly resolved in these studies. The convergence across models is the strength of this evidence, not the precision of any single readout.
Why was SS-31 reclassified from an antioxidant to a cardiolipin-interacting peptide?
The reclassification happened because the antioxidant model could not explain the potency, the structure-activity data or the speed of the observed effects.
Three lines of argument appear repeatedly in the reviews. First, stoichiometry: a scavenger must be present in quantities comparable to the radicals it neutralizes, yet protection in isolated mitochondria is reported at concentrations far below those of the lipid and protein species involved. Second, structure-activity: analogs lacking the phenolic Dmt residue retain activity in the same assays, which is difficult to reconcile with a mechanism that depends on phenol chemistry. Third, kinetics and selectivity: the reported effects on cristae structure and cytochrome c conformation are not what a general radical trap would be expected to produce.
The 2013 ischemia study and the 2014 British Journal of Pharmacology pair are the papers usually cited as the turning point, and the 2014 review First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics makes the reclassification explicit, proposing cardiolipin protection as the organizing principle for the entire body of prior results.
This matters for experimental design. If the compound is modeled as an antioxidant, the natural controls are other antioxidants and the natural readouts are oxidation markers. If it is modeled as a lipid-interacting peptide, the natural controls are membrane composition variants, charge-matched peptides and inactive sequence analogs, and the natural readouts are membrane biophysics, protein conformation and supercomplex organization. Research published since the mid-2010s increasingly uses the second design.
It also matters for interpretation of older data. Results from before the reclassification remain valid as observations, but the mechanistic explanations attached to them in the original discussions should be read as superseded hypotheses rather than as established mechanism. A mechanism review that cites 2004-era conclusions as current understanding is citing the field's first draft.
What did cross-linking proteomics add to the mechanism picture?
Chemical cross-linking mass spectrometry extended the model from lipid binding to a broad map of protein neighbors, reporting that the peptide sits near many inner membrane proteins, with enrichment among cardiolipin-associated and ATP synthesis machinery.
The 2020 Proceedings of the National Academy of Sciences study Mitochondrial protein interaction landscape of SS-31 used a reactive analog of the peptide to capture proximity relationships in mitochondria and reported interactions distributed across a set of mitochondrial proteins rather than concentrated on a single high-affinity partner. The pattern reported there is consistent with an interfacial agent that contacts whatever resides in the cardiolipin-rich membrane neighborhood, and the study also reports evidence that peptide exposure is associated with conformational changes in some of those proteins.
This is the closest the literature comes to an answer for researchers who frame the question as receptor binding. There are protein interaction partners, but they look like neighbors in a membrane domain rather than like a receptor with a ligand. No single protein has been shown to be necessary for the functional effects, and the proteomic data are presented as a landscape rather than as the identification of a target.
Methodological caveats apply. Cross-linking captures proximity, which is not the same as specific binding; reactive analogs differ chemically from the parent peptide; and enrichment analyses depend on the reference proteome and statistical thresholds chosen. The study's own framing is appropriately cautious on these points.
Still, the proteomic work is important because it moved the discussion past a binary question. The useful formulation is not whether SS-31 binds a lipid or a protein, but how a peptide that partitions into a specific lipid microdomain changes the conformational landscape of the protein assemblies embedded there.
What do ischemia and aging models report about downstream function?
Preclinical models report functional improvements in tissues with high mitochondrial demand, most consistently in ischemia-reperfusion and in aged skeletal and cardiac muscle.
In ischemia models, the 2011 and 2013 Journal of the American Society of Nephrology studies report accelerated ATP recovery, preserved mitochondrial structure and reduced tubular injury in rodent kidney ischemia-reperfusion, with the 2013 work tying those outcomes to the cardiolipin interaction through biophysical and biochemical assays run in parallel.
In aging models, the 2013 Aging Cell study Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice reports improved in vivo mitochondrial energetics and fatigue resistance in aged mouse skeletal muscle after short exposure, a time course the authors present as too rapid for mitochondrial biogenesis and therefore consistent with a direct effect on existing membranes. The 2019 Free Radical Biology and Medicine study Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice reports shifts in redox status along with exercise tolerance changes in aged mice, extending the pattern to a longer exposure window.
The common thread across these models is that the reported benefit appears where mitochondrial membranes are compromised. Research suggests the peptide acts on dysfunction rather than enhancing normal function, which is a mechanistically coherent prediction of the cardiolipin model but also a constraint on how broadly the findings should be generalized.
The limits are familiar for preclinical work. Rodent models of ischemia and aging capture some but not all features of human pathophysiology; outcome measures vary across laboratories; exposure windows differ; and publication in this area has been concentrated among a relatively small number of groups, which makes independent replication across the full set of claims an ongoing need rather than a settled fact.
What has the clinical literature reported, and what does it not settle?
Clinical-stage research on elamipretide has reported mixed results, and none of it settles the mechanistic question, because human trials measure outcomes rather than lipid binding.
The 2017 Circulation: Heart Failure report Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide describes a randomized, placebo-controlled study in patients with heart failure with reduced ejection fraction, comparing assigned trial amounts against placebo over a short exposure period, with echocardiographic left ventricular volumes as the primary structural readouts. The study is small and short, and its own discussion frames the findings as hypothesis-generating rather than confirmatory.
Broader clinical programs in mitochondrial myopathy and ophthalmic indications have produced a mixture of positive and null results across endpoints, and the field has not converged on a single validated clinical readout. For a mechanism review, the relevant point is that clinical endpoints are several causal steps removed from cardiolipin association, so a null trial does not refute the lipid-binding model and a positive trial does not confirm it.
What human studies could contribute, in principle, are target engagement measures: evidence that the peptide reaches mitochondrial membranes in the relevant tissue and changes a mechanism-proximal parameter such as phosphocreatine recovery kinetics or a validated redox marker. Several published and ongoing programs have used imaging and functional readouts in this spirit, but the chain from binding to biomarker to outcome remains incompletely mapped in the public record.
Researchers reviewing this literature should therefore keep the two evidence streams separate. The mechanistic case rests on biophysics and isolated mitochondria; the translational case rests on animal models and clinical endpoints; and conflating them is the most common error in secondary write-ups of this compound.
What are the main limits and unresolved questions in the mechanism literature?
The main unresolved questions are whether cardiolipin binding is specific, what the binding geometry is at atomic resolution, and which downstream step is actually necessary for the functional effects.
Specificity is the first open question. The 2020 bilayer study reports association with anionic lipids generally, which raises the possibility that cardiolipin is the relevant target in cells mainly because of its location and abundance in cristae. If that is correct, the compound is better described as an anionic membrane interface modulator with mitochondrial selectivity by distribution, which is a meaningfully different statement from selective cardiolipin recognition.
Binding geometry is the second. There is no published high-resolution structure of the peptide in a native inner membrane. Models drawn from nuclear magnetic resonance, fluorescence, zeta potential measurements and molecular dynamics converge on an interfacial position, but convergence of models is weaker evidence than a structure.
Causality is the third. Cardiolipin binding, surface charge modulation, cytochrome c conformational protection, cristae stabilization and improved coupling are all reported, but the field has not cleanly separated which are causes and which are consequences. A dedicated test would require perturbations that remove one step while leaving the others intact, which is technically difficult in a membrane system.
Two further limits deserve mention. Much of the foundational mechanism work originates from a small number of groups, so independent replication of the key biophysical claims by unrelated laboratories carries disproportionate value. And isolated mitochondria, the workhorse preparation of this literature, lack the cytosolic context, calcium dynamics and quality-control machinery that shape mitochondrial behavior in living cells.
None of this undermines the central observation that a cationic aromatic tetrapeptide concentrates at cardiolipin-rich membranes and changes their behavior. It does mean the mechanism should be stated with its hedges intact.
Which laboratory methods are used to study the cardiolipin interaction?
The methods reported in this literature fall into three groups: membrane biophysics in model systems, functional assays in isolated mitochondria, and proximity or proteomic mapping in intact organelles.
Membrane biophysics includes liposome and micelle preparations of defined lipid composition, nuclear magnetic resonance to probe peptide position relative to head groups and acyl chains, fluorescence approaches that exploit the intrinsic aromatic residues, surface potential and zeta potential measurements to quantify electrostatic changes, and molecular dynamics simulation to generate structural hypotheses. The 2020 Journal of Biological Chemistry study combined several of these to argue for interfacial binding and surface charge modulation.
Functional work in isolated mitochondria includes high-resolution respirometry for oxygen consumption and respiratory control, ATP synthesis measurements, membrane potential readouts with potentiometric dyes, swelling assays for permeability transition, cytochrome c peroxidase activity assays, and electron microscopy for cristae morphology. The ischemia and aging studies cited above draw on these methods in various combinations.
Proximity mapping is the newest layer, exemplified by cross-linking mass spectrometry with reactive peptide analogs, which produces interaction landscapes rather than single-target identifications.
For laboratories planning work in this area, the practical reporting variables are compound identity, lipid composition, preparation state of the mitochondria and the concentration range studied.
How do laboratories source and verify SS-31 for mechanistic work?
Laboratories verify identity and lot-specific analytics before procurement, then match the material's documented characteristics to the requirements of the planned assay.
Mechanistic work on a membrane-interacting peptide is sensitive to identity and composition, because sequence errors, counterion differences and residual synthesis byproducts can all change how a cationic peptide partitions into a bilayer. The standard verification steps are confirming the sequence and molecular identity, checking the compound's CAS number against the supplier's documentation, and reviewing the analytical certificate issued for the specific lot being supplied rather than a generic specification sheet.
Real Peptides supplies SS-31 (elamipretide) as a research-use-only compound, and the dedicated SS-31 compound page collects background on the peptide for researchers evaluating it. Independent third-party testing is performed on every batch, and the resulting certificates of analysis are published and publicly verifiable at /coas/, so the documentation for a given lot can be reviewed before an order is placed. The broader research catalog is listed in the shop, and company location details are published at /location/.
What a certificate of analysis supports, in this context, is traceability: a researcher can tie the material in hand to a specific analytical record, which matters when a mechanism result needs to be reproduced months later or defended in review. It does not substitute for in-house confirmation where an assay demands it, and laboratories working at the biophysical end of this field commonly run their own identity checks regardless of supplier documentation.
Finally, record-keeping around storage condition, lot number and solvent system belongs in the experimental record for any membrane-interaction study, because partitioning behavior is the readout and anything that changes the peptide's effective concentration or aggregation state changes the result.
All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.
References
- Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry. 2004. PMID: 15178689. pubmed.ncbi.nlm.nih.gov/15178689
- Cell-permeable, mitochondrial-targeted, peptide antioxidants. The AAPS Journal. 2006. PMID: 16796378. pubmed.ncbi.nlm.nih.gov/16796378
- Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. Journal of the American Society of Nephrology. 2011. PMID: 21546574. pubmed.ncbi.nlm.nih.gov/21546574
- The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013. PMID: 23813215. pubmed.ncbi.nlm.nih.gov/23813215
- Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell. 2013. PMID: 23692570. pubmed.ncbi.nlm.nih.gov/23692570
- Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology. 2014. PMID: 24134698. pubmed.ncbi.nlm.nih.gov/24134698
- First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014. PMID: 24117165. pubmed.ncbi.nlm.nih.gov/24117165
- Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clinical Pharmacology and Therapeutics. 2014. PMID: 2574731. pubmed.ncbi.nlm.nih.gov/2574731
- Disruption of cytochrome c heme coordination is responsible for mitochondrial injury during ischemia. Biochimica et Biophysica Acta. 2015. PMID: 26071084. pubmed.ncbi.nlm.nih.gov/26071084
- Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circulation: Heart Failure. 2017. PMID: 29217757. pubmed.ncbi.nlm.nih.gov/29217757
- Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radical Biology and Medicine. 2019. PMID: 30597195. pubmed.ncbi.nlm.nih.gov/30597195
- The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry. 2020. PMID: 32273339. pubmed.ncbi.nlm.nih.gov/32273339
- Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences. 2020. PMID: 32554501. pubmed.ncbi.nlm.nih.gov/32554501
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA